# Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

> **NCT07246889** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ausper Biopharma Co., Ltd.** · enrollment: 577 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** AHB-137
- **DRUG:** Placebo
- **DRUG:** NA therapy

## Key facts

- **NCT ID:** NCT07246889
- **Lead sponsor:** Ausper Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2026-12-18
- **Final completion:** 2027-10-31
- **Target enrollment:** 577 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246889, "Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07246889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*